NEW YORK, Nov 6 (Reuters) - Goldman Sachs sold 1.3 million shares of Valeant Pharmaceuticals International on Thursday, a day when the drug company's shares fell as much as 20 percent, because they were securing loans made to Valeant CEO Michael Pearson that needed to be paid.